Pinto Joshua 4

Accession 0000950170-25-079908

CIK 0001885522other

View on SEC.gov Company Profile

Filed

May 29, 8:00 PM ET

Accepted

May 30, 6:25 PM ET

Size

34.8 KB

Accession

0000950170-25-079908

Insider Transaction Report

Form 4

Period: 2025-05-28

Neumora Therapeutics, Inc.NMRA

Pinto Joshua

President

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−270,828→ 0 total
Exercise: $1.69Exp: 2031-06-07→ Common Stock (270,828 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+170,000→ 170,000 total
Exercise: $0.72Exp: 2034-02-14→ Common Stock (170,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−223,034→ 0 total
Exercise: $1.69Exp: 2031-06-07→ Common Stock (223,034 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+223,034→ 223,034 total
Exercise: $0.72Exp: 2031-06-07→ Common Stock (223,034 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−720,084→ 0 total
Exercise: $1.69Exp: 2032-01-27→ Common Stock (720,084 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−127,448→ 0 total
Exercise: $1.69Exp: 2033-06-23→ Common Stock (127,448 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+720,084→ 720,084 total
Exercise: $0.72Exp: 2032-01-27→ Common Stock (720,084 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+3,000,000→ 3,000,000 total
Exercise: $0.72Exp: 2035-02-13→ Common Stock (3,000,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−170,000→ 0 total
Exercise: $1.69Exp: 2034-02-14→ Common Stock (170,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−3,000,000→ 0 total
Exercise: $1.69Exp: 2035-02-13→ Common Stock (3,000,000 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+270,828→ 270,828 total
Exercise: $0.72Exp: 2031-06-07→ Common Stock (270,828 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+127,448→ 127,448 total
Exercise: $0.72Exp: 2033-06-23→ Common Stock (127,448 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−223,034→ 0 total
Exercise: $1.69Exp: 2031-06-07→ Common Stock (223,034 underlying)
Award
Stock Option (Right to Buy)
2025-05-28+223,034→ 223,034 total
Exercise: $0.72Exp: 2031-06-07→ Common Stock (223,034 underlying)

Footnotes (9)

[F1]1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
[F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged.
[F3]The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date.
[F4]The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date.
[F5]25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F6]25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F7]25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F8]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F9]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

→

Entity typeother

Related Parties

filerCIK 0001992595

Filing Metadata

Form type: 4
Filed: May 29, 8:00 PM ET
Accepted: May 30, 6:25 PM ET
Size: 34.8 KB

View on SEC.gov